Adjuvant durvalumab for esophageal squamous cell carcinoma after neoadjuvant chemoradiotherapy: a placebo-controlled, randomized, double-blind, phase II study

BACKGROUND: We evaluated the efficacy of adjuvant durvalumab after neoadjuvant concurrent chemoradiotherapy (CCRT) in patients with esophageal squamous cell carcinoma (ESCC). PATIENTS AND METHODS: This randomized, double-blind, phase II study included patients with ESCC who underwent curative surger...

Descripción completa

Detalles Bibliográficos
Autores principales: Park, S., Sun, J.-M., Choi, Y.-L., Oh, D., Kim, H.K., Lee, T., Chi, S.A., Lee, S.-H., Choi, Y.S., Jung, S.-H., Ahn, M.-J., Ahn, Y.C., Park, K., Shim, Y.M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8850741/
https://www.ncbi.nlm.nih.gov/pubmed/35158205
http://dx.doi.org/10.1016/j.esmoop.2022.100385

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8850741/
https://www.ncbi.nlm.nih.gov/pubmed/35158205
http://dx.doi.org/10.1016/j.esmoop.2022.100385

Ejemplares similares